G&G Biotechnology Ltd

G&G Biotechnology Ltd develops innovative biotechnology solutions, particularly in aesthetic and reconstructive surgery, focusing on lightweight silicone implants that enhance patient comfort and satisfaction. Founded in 2006 and headquartered in Haifa, Israel, G&G Biotechnology Ltd specializes in biotechnology products for aesthetic and reconstructive procedures. The company has raised venture financing in the past, with the last funding round occurring on June 1, 2015, led by Sequoia Capital, which supported their growth initiatives. Dael Govreen-Segal serves as the CEO, overseeing the company's strategies and operations.

G&G Biotechnology Ltd is known for its B-Lite® implant, a significant advancement in breast implant technology that reduces weight by up to 30% while maintaining volume. The company offers a diverse range of over 2,000 customizable silicone breast and body-contouring implants tailored to meet aesthetic and medical needs. Their products are distributed globally, catering to plastic surgeons and aesthetic clinics across more than 90 countries, including regions in North America, Europe, and Asia. G&G Biotechnology Ltd generates revenue through B2B sales to healthcare providers such as clinics and hospitals, primarily focusing on bulk orders for breast augmentation and reconstruction procedures.

Their product offerings, including the B-Lite® and traditional silicone implants, significantly contribute to revenue streams, which are further supported by a warranty program called IMPLANTS OF EXCELLENCE, enhancing customer loyalty. The company plans to continue its development of new products, including further innovations in lightweight implant technology. G&G Biotechnology Ltd aims to expand its market presence in emerging regions, targeting specific growth in Asia by the end of 2025. The funding received in 2015 will be utilized to support these advancements and market expansions, allowing the company to enhance its offerings and reach a broader clientele.